JN3
CHENODEOXYCHOLIC ACID
Created: | 2007-01-02 |
Last modified: | 2021-03-13 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 68 |
Chiral Atom Count | 10 |
Bond Count | 71 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | CHENODEOXYCHOLIC ACID |
Synonyms | (3ALPHA,5ALPHA,7BETA,8ALPHA,17ALPHA)-3,7-DIHYDROXYCHOLAN-24-OIC ACID |
Systematic Name (OpenEye OEToolkits) | (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
Formula | C24 H40 O4 |
Molecular Weight | 392.572 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C(O)CCC(C4C3(C(C1C(C2(C(CC1O)CC(O)CC2)C)CC3)CC4)C)C |
SMILES | CACTVS | 3.341 | C[CH](CCC(O)=O)[CH]1CC[CH]2[CH]3[CH](O)C[CH]4C[CH](O)CC[C]4(C)[CH]3CC[C]12C |
SMILES | OpenEye OEToolkits | 1.5.0 | CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C |
Canonical SMILES | CACTVS | 3.341 | C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C |
InChI | InChI | 1.03 | InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1 |
InChIKey | InChI | 1.03 | RUDATBOHQWOJDD-BSWAIDMHSA-N |
Drug Info: DrugBank
DrugBank ID | DB06777 |
---|---|
Name | Chenodeoxycholic acid |
Groups | approved |
Description | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated. |
Synonyms |
|
Brand Names |
|
Indication | Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones. |
Categories |
|
ATC-Code | A05AA01 |
CAS number | 474-25-9 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Bile acid receptor | MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQN... | unknown | other |
Nuclear receptor subfamily 1 group I member 2 | MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATG... | unknown | |
G-protein coupled bile acid receptor 1 | MTPNSTGEVPSPIPKGALGLSLALASLIITANLLLALGIAWDRRLRSPPA... | unknown | |
Aldo-keto reductase family 1 member C2 | MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHID... | unknown | substrate |
Sterol 26-hydroxylase, mitochondrial | MAALGCARLRWALRGAGRGLCPHGARAKAAIPAALPSDKATGAPGAGPGV... | unknown | substrate |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL240597 |
PubChem | 10133 |
ChEMBL | CHEMBL240597 |
ChEBI | CHEBI:16755 |
CCDC/CSD | SIFGOD |